Helen Torley joins Onyx Pharmaceuticals
Takes the position of executive vp and chief commercial officer
Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.
Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.
From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.
Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.
You may also like
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia
AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical
ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research
ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine